We are live on ! Find out more
JNP

Juniper Pharmaceuticals, Inc. Common Stock
JNP

Delisted

JNP was delisted on the 13th of August, 2018.

42 hedge funds and large institutions have $18.1M invested in Juniper Pharmaceuticals, Inc. Common Stock in 2015 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 11 increasing their positions, 12 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

167% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 3

66% more call options, than puts

Call options by funds: $497K | Put options by funds: $300K

28% more capital invested

Capital invested by funds: $14.2M → $18.1M (+$3.91M)

14% more funds holding

Funds holding: 3742 (+5)

8% less repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 12

Holders
42
Holders Change
+5
Holders Change %
+13.51%
% of All Funds
1.12%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
8
Increased
11
Reduced
12
Closed
3
Calls
$497K
Puts
$300K
Net Calls
+$197K
Net Calls Change
+$197K

JNP Hedge Fund Activity: Q1 2015 in Review

42 of the 3,754 institutional investors tracked by Wall St. Rank reported a position in Juniper Pharmaceuticals, Inc. Common Stock (JNP) for Q1 2015, worth a combined $18.1M — up 28% from $14.2M a quarter earlier.

Buyers outnumbered sellers: 8 funds opened new JNP positions and 3 closed out — a net gain of 5 holders — while 11 added to existing stakes and 12 trimmed.

The largest buyer was JW Asset Management, adding an estimated $578K. The largest seller was Royal Bank of Canada, cutting an estimated $388K.

  • 42 institutional investors held Juniper Pharmaceuticals, Inc. Common Stock (JNP) as of Q1 2015, up from 37 in Q4 2014.
  • Funds reported $18.1M of Juniper Pharmaceuticals, Inc. Common Stock stock for Q1 2015, up 28% quarter-over-quarter.
  • 8 funds opened new Juniper Pharmaceuticals, Inc. Common Stock positions in Q1 2015 and 3 closed out, a net change of +5 holders.
  • The largest Juniper Pharmaceuticals, Inc. Common Stock buyer in Q1 2015 was JW Asset Management, an estimated $578K added.
  • The largest Juniper Pharmaceuticals, Inc. Common Stock seller in Q1 2015 was Royal Bank of Canada, an estimated $388K sold.

Based on aggregated 13F filings for Q1 2015.